Resveratrol as MDR reversion molecule in breast cancer: An overview

Abstract

Breast cancer is the most common cause of cancer mortality among women worldwide; therefore, a strategy to defeat breast cancer is an extremely important medical issue. One of the major challenges in this regard is multidrug resistance (MDR). Resveratrol, a well-known phytoestrogen, may be helpful as part of an overall strategy to defeat breast cancer. The mixed agonist and antagonist role of resveratrol for the estrogen receptor makes it a controversial but interesting molecule in cancer therapy, especially in hormone dependent cancers. Several in vitro investigations have suggested that resveratrol can reverse multidrug resistance. However, poor bioavailability of resveratrol is a potential limitation for resveratrol treatment and cancer outcome in vivo. Fortunately, combination therapy with other selected compounds improves resveratrol's bioavailability and/or a delay in its metabolism. This review summaries the available published literature dealing with the effects of resveratrol on multidrug resistance in cancer and more specifically, breast cancer.

Quantitative Analysis of Proteome in Non-functional Pituitary Adenomas: Clinical Relevance and Potential Benefits for the Patients

“…Binding of integrin to ECM resulted in phosphorylation of FAK at several tyrosine residues including Tyr397 to increase kinase activities and promote the interaction of FAK with other proteins including SRC (30)(31)(32). One study found that FAK directly bond to cortactin (an actin regulator), which was not only a key force movement and focal adhesion conversion, but also affected cell survival (33). This study found 35 molecules (DEGs; proteins) distributed in this pathway (Supplemental Table 9), which suggested that the biological behavior of NFPA should be similar to that of other tumors, and that there should be a huge difference in cell adhesion between NFPAs and normal pituitaries.…”

“…It has been reported that cGMP promoted tumorigenesis and anticancer effects. For example, the activated cGMP/PKG pathway induced multiple cancers (33,(35)(36)(37). Studies found specifically activated protein kinase G1 (PKG1) triggered MAPK signaling pathway to promote growth of melanoma (38).…”

Involvement of ABC transporters in the efflux and toxicity of MPA‐COOH‐CdTe quantum dots in human breast cancer SK‐BR‐3 cells

“…On the other hand, ABC transporter‐mediated multidrug resistance is one of the main obstacles for the successful treatment of cancer, because of their ability to pump drugs out of the cells . Drug delivery on the basis of nanoparticles, including gold, silver, quantum dots (QDs), titanium dioxide, carbon‐based nanomaterial, is a promising tool to overcome the drug resistance caused by ABC transporters.…”

Dielectrophoretic trapping of single leukemic cells using the conventional and compact optical measurement systems

“…Leukemia patients whose tumor cells are MDR could benefit from treatment using various MDR inhibitors, ranging from conventional ones such as: verapamil to less toxic ones . For instance, the recent use of dual‐drug delivery systems based on nanoparticles and chemotherapeutic agents can interfere with the P‐gp drug pumps and lead to enhancement of drug accumulation in the leukemic cells . Several trials show encouraging results in using cyclosporine A (CsA) in the treatment of AML patients , but perhaps the most prominent application for using MDR inhibitors was provided by Chan et al., in which a high cure rate (91%) was achieved by using CsA in combination with chemotherapy .…”